---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000487"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-11-05T23:59:59+00:00"
generated_at: "2026-06-28T12:07:34.281367+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma reduces convertible note principal by $967,830 via equity and cash

## Summary
- Satisfied $967,830 of principal and $539,392 in fees/interest through 706M common shares, 23.7M Series A preferred, and $218,529 cash.
- Outstanding convertible note principal fell from $2.36M (June 30, 2021) to $1.40M (November 4, 2021).
- Total debt reduction of approximately $1.51M includes principal, fees, penalties, and accrued interest.

## SEC filing metadata
- accession: 0001607062-21-000487
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-11-05T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000487/0001607062-21-000487-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000487/rgbp110521form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000487
- JSON: https://secwatch.observer/filing/0001607062-21-000487.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000487.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.